General Comments / Chat, page-9111

There would have to be dozens of pathways to commercialisation - but I think the best (perhaps only) non-dilutive funding strategy would be to license AML/RC110. AML is a niche indication and Sheba 2.0 provides the platform to license this opportunity*.

*I have assumed Sheba 2.0 will be positive given the 50% response rate achieved with sub-optimal p1 dosing and the fact they are submitting the p2 data to ASH.

Given AML's 'niche' status, the blue sky market potential here is limited, relative to other indications. I can't understand why you would spend the limited capital on hand to further this opportunity, when licensing it now, with positive p2 mono and combination therapy readouts, could fund additional programs in 'new' indications.

"There is lean and then there is fumes from an oily rag". Totally agree with this statement.

Yes, running trials in Australia might be cheaper, and we may be reimbursed significantly, but at what cost? Race have still never dosed a patient. Outsource the mBC trial to the likes of Sheba/CoH/MD Anderson and get it moving. It might be more expensive, but we can't afford to keep farting around here. Therapeutic validation of FTO/Cardioprotection is the company maker. Pursue it with whatever means necessary IMO.

I'm also hoping they haven't totally abandoned lung/pd-1. Further validation of FTO + PD-1 synergy just pre-published:

https://www.researchsquare.com/article/rs-3381071/v1